Evaluation of Pre-treatment Risk Factors for Development of Trastuzumab Deruxtecan Associated Pneumonitis

被引：0
|
作者：
Ahmed, O. [1 ]
Henricks, J. [1 ]
Haddad, T. [1 ]
Ma, J. [1 ]
Esguerra, V. G. [1 ]
Wang, J. [1 ]
Wert, M. J. [1 ]
Gatti-Mays, M. [2 ]
Ho, K. [1 ]
机构：
[1] Ohio State Univ, Columbus, OH USA
[2] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1846
引用
收藏
页数：2
相关论文
共 50 条
  • [1] INCIDENCE AND RISK FACTORS FOR PNEUMONITIS DUE TO TRASTUZUMAB DERUXTECAN IN FEMALES WITH BREAST CANCER
    Azhar, Maria
    Soto, Felipe
    Vazquez-Gonzalez, Norma Alicia
    Su, Amber
    Mouabbi, Jason
    Faiz, Saadia A.
    Sheshadri, Ajay
    CHEST, 2024, 166 (04) : 3513A - 3514A
  • [2] Trastuzumab deruxtecan-related risk of ILD and pneumonitis
    Reactions Weekly, 2024, 2008 (1) : 12 - 12
  • [3] Trastuzumab deruxtecan: risk of interstitial lung disease/pneumonitis
    Reactions Weekly, 2022, 1915 (1) : 10 - 10
  • [4] Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
    Henricks, Jonathan
    Haddad, Tyler
    Ahmed, Omair
    Schoenhals, Jonathan
    Kumar, Pavnesh
    Wilson, Ryan
    Ma, Jianing
    Wang, Jing Gennie
    Wert, Michael
    Esguerra, Vincent
    Bentley, Ian
    Johnson, Kai
    Stover, Daniel
    Jhawar, Sachin R.
    Gatti-Mays, Margaret
    Ho, Kevin
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [5] Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan-associated pneumonitis
    Abelman, Rachel Occhiogrosso
    Hartley-Blossom, Zachary
    Fell, Geoffrey G.
    Ryan, Phoebe
    Nakajima, Erika
    Moy, Beverly
    Ellisen, Leif W.
    Bardia, Aditya
    Fintelmann, Florian J.
    Spring, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Development of An Automated Pre-Treatment Plan Evaluation
    Rembish, J.
    Myers, P.
    Kabat, C.
    Bice, N.
    Rasmussen, K.
    Saenz, D.
    Kirby, N.
    Papanikolaou, N.
    Stathakis, S.
    MEDICAL PHYSICS, 2021, 48 (06)
  • [7] Development of An Automated Pre-Treatment Data-Transfer Evaluation
    Rembish, J.
    Bice, N.
    Kabat, C.
    Stathakis, S.
    Papanikolaou, N.
    Myers, P.
    MEDICAL PHYSICS, 2020, 47 (06) : E744 - E744
  • [8] PRE-TREATMENT INTERSTITIAL ABNORMALITIES IS A RISK FACTOR FOR IMMUNE CHECKPOINT INHIBITOR PNEUMONITIS IN PATIENTS WITH LUNG CANCER
    Wong, Alexander
    Riley, Maria
    Zhao, Songzhu
    Zimmer, Jessica
    Viveiros, Matthew
    Wang, Jing Gennie
    Esguerra, Vince
    Li, Mingjia
    Lopez, Gabrielle
    Otterson, Gregory
    Kendra, Kari
    Presley, Carolyn
    Wei, Lai
    Owen, Dwight
    Ho, Kevin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A463 - A463
  • [9] Pre-treatment factors associated with detecting additional brain metastases at stereotactic radiosurgery
    Zabi Wardak
    Alexander Augustyn
    Hong Zhu
    Bruce E. Mickey
    Louis A. Whitworth
    Christopher J. Madden
    Samuel L. Barnett
    Ramzi E. Abdulrahman
    Lucien A. Nedzi
    Robert D. Timmerman
    Kevin S. Choe
    Journal of Neuro-Oncology, 2016, 128 : 251 - 257
  • [10] Prevalence and risk factors for pre-treatment pain in oral cancer; a retrospective analysis
    Nasir, Khawaja S.
    Jamshed, Arif
    Hussain, Raza
    ANNALS OF ONCOLOGY, 2021, 32 : S342 - S342
12345